Skip to main content

Purpura, Thrombocytopenic, Idiopathic

6
Pipeline Programs
13
Companies
11
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
2
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 12 programs with unclassified modality

Competitive Landscape

13 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
1
PrednisonePhase 4
rhIL-11N/A1 trial
Active Trials
NCT01317966Withdrawn0Est. Mar 2012
Autonomous Therapeutics
1 program
1
PrednisonePhase 41 trial
Active Trials
NCT01356511Completed261Est. Mar 2015
Sandoz
SandozAustria - Kundl
1 program
1
Eltrombopag TabletsPhase 31 trial
Active Trials
NCT02201290Completed9Est. Jul 2017
Prothya Biosolutions
Prothya BiosolutionsBelgium - Brussels
1 program
1
IVIG-LPhase 31 trial
Active Trials
NCT00151840Completed20Est. Mar 2002
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
veltuzumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT00547066Terminated48Est. Nov 2011
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
EltrombopagPhase 1
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
2 programs
veltuzumabPHASE_1_2Monoclonal Antibody
veltuzumabPHASE_1_2Monoclonal Antibody
Roche
RocheSTAVANGER NORWAY, Norway
1 program
The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.N/A1 trial
Active Trials
NCT01101295Unknown250Est. Apr 2017
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
BI 655064PHASE_11 trial
Active Trials
NCT02009761Terminated6Est. Apr 2016
Eisai
EisaiChina - Liaoning
1 program
E5501 40 mg 2 x 20-mg tablets, orally, fastedPHASE_11 trial
Active Trials
NCT01327872Completed84Est. Jun 2011
GSK
GSKLONDON, United Kingdom
1 program
EltrombopagPHASE_11 trial
Active Trials
NCT02281370Completed39Est. Dec 2014
Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
1 program
Fostamatinib Disodium / R935788PHASE_21 trial
Active Trials
NCT00706342Completed18Est. Apr 2010
Grifols
GrifolsNEW YORK, NY
1 program
Immune Globulin IV [Human], 10% Caprylate/Chromatography PurifiedPHASE_21 trial
Active Trials
NCT00220727Completed8Est. Oct 2003

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Autonomous TherapeuticsPrednisone
SandozEltrombopag Tablets
Prothya BiosolutionsIVIG-L
Rigel PharmaceuticalsFostamatinib Disodium / R935788
GrifolsImmune Globulin IV [Human], 10% Caprylate/Chromatography Purified
Kite Pharmaveltuzumab
GSKEltrombopag
Boehringer IngelheimBI 655064
EisaiE5501 40 mg 2 x 20-mg tablets, orally, fasted
UNION therapeuticsrhIL-11
RocheThe ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.

Clinical Trials (11)

Total enrollment: 743 patients across 11 trials

NCT01356511Autonomous TherapeuticsPrednisone

High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Start: Sep 2010Est. completion: Mar 2015261 patients
Phase 4Completed
NCT02201290SandozEltrombopag Tablets

A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Start: Jun 2013Est. completion: Jul 20179 patients
Phase 3Completed
NCT00151840Prothya BiosolutionsIVIG-L

Efficacy and Safety of IVIG-L in ITP Patients

Start: Oct 2001Est. completion: Mar 200220 patients
Phase 3Completed
NCT00706342Rigel PharmaceuticalsFostamatinib Disodium / R935788

Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

Start: Jan 2007Est. completion: Apr 201018 patients
Phase 2Completed
NCT00220727GrifolsImmune Globulin IV [Human], 10% Caprylate/Chromatography Purified

Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP

Start: Jul 2003Est. completion: Oct 20038 patients
Phase 2Completed
NCT00547066Kite Pharmaveltuzumab

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

Start: Nov 2007Est. completion: Nov 201148 patients
Phase 1/2Terminated
NCT02281370GSKEltrombopag

Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects

Start: Nov 2014Est. completion: Dec 201439 patients
Phase 1Completed
NCT02009761Boehringer IngelheimBI 655064

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

Start: Dec 2013Est. completion: Apr 20166 patients
Phase 1Terminated
NCT01327872EisaiE5501 40 mg 2 x 20-mg tablets, orally, fasted

Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects

Start: Feb 2011Est. completion: Jun 201184 patients
Phase 1Completed
NCT01317966UNION therapeuticsrhIL-11

Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia

Start: Mar 2011Est. completion: Mar 20120
N/AWithdrawn
NCT01101295RocheThe ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.

The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.

Start: Apr 2010Est. completion: Apr 2017250 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
13 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.